Steven Buechler Discusses EarlyR Gene Signature in the BIG 1-98 Trial for Breast Cancer

Steven Buechler
Published: Friday, Jan 06, 2017



Steven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the Breast International Group (BIG) 1-98 study. This randomized, double-blind, phase III trial compared letrozole with tamoxifen as an adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.

Although many patients in the BIG 1-98 trial demonstrated positive outcomes, Buechler says that there is still a small set of very high-risk patients who are ER-positive who could benefit from more aggressive therapy. These are patients who are likely to have a recurrence, so the side effects from a taxane-based chemotherapy regimen are worth the risk, says Buechler.

Many high-risk patients have amplification in chromosome 8 where the MYC gene is. MYC amplification has been associated with taxane sensitivity. Therefore, genomic data suggest that a taxane may be effective.
 


Steven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the Breast International Group (BIG) 1-98 study. This randomized, double-blind, phase III trial compared letrozole with tamoxifen as an adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.

Although many patients in the BIG 1-98 trial demonstrated positive outcomes, Buechler says that there is still a small set of very high-risk patients who are ER-positive who could benefit from more aggressive therapy. These are patients who are likely to have a recurrence, so the side effects from a taxane-based chemotherapy regimen are worth the risk, says Buechler.

Many high-risk patients have amplification in chromosome 8 where the MYC gene is. MYC amplification has been associated with taxane sensitivity. Therefore, genomic data suggest that a taxane may be effective.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x